Oil prices rebound sharply on smaller-than-feared OPEC+ output hike
SAN DIEGO/ST. GALLEN - FILSPARI (sparsentan) has been recognized as a potential first-line treatment for IgA nephropathy (IgAN) patients at risk of progressive kidney function loss in the updated 2025 KDIGO clinical practice guidelines, according to a press release from CSL Vifor and Travere Therapeutics (NASDAQ:TVTX). The announcement comes as Travere, with a market capitalization of $2.19 billion, has seen its stock surge over 63% in the past year, according to InvestingPro data.
The updated guidelines define remission of proteinuria (below 0.5 g/day, ideally below 0.3 g/day) and slowing estimated glomerular filtration rate (eGFR) decline as key treatment goals for IgAN patients. The guidelines suggest that treatment with FILSPARI, a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), may be an appropriate first-line approach to manage IgAN-induced nephron loss, as an alternative to the traditional RASi-first approach. This development has contributed to Travere’s impressive revenue growth of 87.94% over the last twelve months.
"The updated KDIGO guidance represents an important step forward for the IgA Nephropathy community," said Prof. Dr. med. Jürgen Floege, Senior Professor at the University Hospital, RWTH Aachen, Germany. "For patients and clinicians, this provides greater clarity and confidence in navigating treatment decisions."
The guidelines highlight FILSPARI as the only therapy with proven efficacy compared to optimized RASi in clinical trials. The PROTECT Study, one of the largest interventional studies in IgAN, demonstrated that after 36 weeks, patients receiving FILSPARI achieved a mean reduction in proteinuria of 49.8% from baseline, compared to 15.1% for irbesartan-treated patients.
IgAN, also called Berger’s disease, is characterized by the buildup of immunoglobulin A in the kidneys, leading to proteinuria and progressive loss of kidney function. It affects up to 150,000 people in the U.S. and is a leading cause of kidney failure due to glomerular disease.
FILSPARI is approved for IgAN treatment in the United States and Europe, and has been launched in Germany, Austria, Switzerland, Luxembourg and the UK. The medication carries boxed warnings for hepatotoxicity and embryo-fetal toxicity, and is available only through a restricted program called the FILSPARI REMS. With analysts maintaining a Strong Buy consensus and setting price targets up to $47, detailed analysis of Travere’s growth potential is available through InvestingPro’s comprehensive research reports, which cover over 1,400 US stocks with expert insights and detailed financial metrics.
The information in this article is based on a press release statement from CSL Vifor and Travere Therapeutics.
In other recent news, Travere Therapeutics has been the subject of several updates from research firms. H.C. Wainwright reiterated its Buy rating and maintained a $47.00 price target on Travere Therapeutics, highlighting the company’s adapted Risk Evaluation and Mitigation Strategy (REMS) as a competitive advantage. The firm noted that the reduced REMS requirements for Travere’s drug FILSPARI are beneficial, especially in competition with Novartis’s Vanrafia. Additionally, Jefferies also maintained a Buy rating with a $35.00 price target, viewing the cancellation of an FDA advisory committee meeting for Travere’s FSGS indication as a positive sign of support for the drug’s approval process. The FDA’s decision to cancel the advisory committee meeting for FILSPARI’s supplemental New Drug Application (sNDA) in focal segmental glomerulosclerosis (FSGS) marks a significant development. Travere announced that the PDUFA date for the regulatory decision remains January 13, 2026. Furthermore, the Kidney Disease: Improving Global Outcomes (KDIGO) organization recently published its final 2025 Clinical Practice Guidelines for IgA Nephropathy, which Travere announced on September 18.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.